Xenon Pharmaceuticals - Common Shares (XENE) closed at $40.45 on November 9, 2026, up 3.3% from the previous close, on volume of 1,445,147 shares (30-day average 1,543,429).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 13, 2026 | Call with Delta Hedge | 16-Apr-27 37.5 C +22,400 Stock | 400 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Xenon Reports Third-Quarter 2026 Results and Business Update
TipRanks (Mon, 9-Nov 5:28 PM ET)
Xenon Pharma GAAP EPS of -$1.11 beats by $0.03
Seeking Alpha News (Mon, 9-Nov 4:31 PM ET)
Xenon Reports Q3 2026 Financial Results and Provides Business Update
Globe Newswire (Mon, 9-Nov 4:01 PM ET)
Xenon to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Xenon to Report Q3 2026 Financial Results on November 9, 2026
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 30-Oct 4:01 PM ET)
Globe Newswire (Thu, 29-Oct 8:30 AM ET)
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Globe Newswire (Tue, 20-Oct 8:50 PM ET)
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
Business Wire (Wed, 23-Sep 12:23 AM ET)
PRNewswire (Tue, 22-Sep 6:18 PM ET)
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Xenon Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol XENE.
As of November 9, 2026, XENE stock price climbed to $40.45 with 1,445,147 million shares trading.
XENE has a beta of 0.35, meaning it tends to be less sensitive to market movements. XENE has a correlation of 0.01 to the broad based SPY ETF.
XENE has a market cap of $3.92 billion. This is considered a Mid Cap stock.
Last quarter Xenon Pharmaceuticals - Common Shares reported $0 in Revenue and -$1.11 earnings per share. This fell short of revenue expectation by $-937,500 and exceeded earnings estimates by $.05.
In the last 3 years, XENE traded as high as $72.66 and as low as $26.74.
The top ETF exchange traded funds that XENE belongs to (by Net Assets): IWM, IWO, IBB, TCAF, VTWO.
XENE has underperformed the market in the last year with a return of +5.6%, while the SPY ETF gained +13.4%. In the last 3 month period, XENE fell short of the market, returning -37.3%, while SPY returned -1.8%. However, in the most recent 2 weeks XENE has outperformed the stock market by returning +14.5%, while SPY returned -1.0%.
XENE support price is $38.18 and resistance is $40.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XENE shares will trade within this expected range on the day.
